FY2025 Earnings Forecast for Denali Therapeutics Inc. (NASDAQ:DNLI) Issued By Zacks Research

Denali Therapeutics Inc. (NASDAQ:DNLI) – Analysts at Zacks Research cut their FY2025 earnings per share (EPS) estimates for Denali Therapeutics in a research note issued on Wednesday, June 19th. Zacks Research analyst A. Chakraborty now forecasts that the company will earn ($2.86) per share for the year, down from their previous forecast of ($2.83). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.78) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q4 2025 earnings at ($0.72) EPS, Q1 2026 earnings at ($0.68) EPS and FY2026 earnings at ($2.76) EPS.

Other research analysts have also recently issued reports about the company. The Goldman Sachs Group reduced their price objective on Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. UBS Group reduced their price target on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, April 9th. Wedbush reduced their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and set a $95.00 price target on shares of Denali Therapeutics in a report on Wednesday, May 8th. Finally, Stifel Nicolaus reduced their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, May 8th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $40.22.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $22.63 on Monday. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $31.03. The company has a market capitalization of $3.23 billion, a PE ratio of -23.57 and a beta of 1.37. The business’s fifty day moving average is $18.88 and its 200 day moving average is $19.16.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter in the prior year, the company earned ($0.80) EPS.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 92,500 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the transaction, the director now owns 47,341 shares of the company’s stock, valued at approximately $970,490.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Denali Therapeutics news, Director Steve E. Krognes sold 92,500 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the transaction, the director now owns 47,341 shares of the company’s stock, valued at approximately $970,490.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 1,666 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the transaction, the director now directly owns 118,043 shares of the company’s stock, valued at approximately $2,159,006.47. The disclosure for this sale can be found here. Insiders sold 95,624 shares of company stock worth $1,958,403 in the last three months. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its position in shares of Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after acquiring an additional 1,376 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Denali Therapeutics by 48.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after acquiring an additional 807 shares during the period. Fisher Asset Management LLC purchased a new position in shares of Denali Therapeutics during the fourth quarter worth approximately $59,000. Assetmark Inc. increased its position in shares of Denali Therapeutics by 65.3% during the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock worth $76,000 after acquiring an additional 1,402 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of Denali Therapeutics during the first quarter worth approximately $88,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.